Adagene (ADAG) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed PepGen (PEPG) over the past year, gaining 42.2% versus a loss of 51.1%. PepGen is the larger company by market cap ($180.2 million vs $179.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | PEPG |
|---|---|---|
| Share price | $2.67 | $2.61 |
| Market cap | $179.27M | $180.19M |
| 1-day change | -3.96% | +9.45% |
| YTD return | +47.09% | -63.44% |
| 1-year return | +42.20% | -51.13% |
| 5-year return | -76.24% | — |
| EPS (TTM) | $-0.37 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $7.80 |
| 52-week low | $1.30 | $1.31 |
| Distance from 52-week high | -44.95% | -66.60% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +271.16% | +291.17% |
| Average volume | 244.76K | 946.80K |
| Shares outstanding | 67.14M | 69.17M |
| Employees | 128 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed PEPG by 93.3 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ADAG vs PEPG FAQ
Which is bigger, Adagene or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $180.19M compared with $179.27M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or PEPG?
ADAG returned +42.20% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.